Compare Adaptive Biotechnologies Corp (ADPT) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Goodyear Tire & Rubber Co — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Goodyear Tire & Rubber Co trades at $6.51 (market cap $2.02B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| ADPT | GT | |
|---|---|---|
Market Cap | $3.33B | $2.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $11.55 |
52-Week Low | $10.24 | $5.58 |
Enterprise Value | $3.19B | $9.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Goodyear Tire & Rubber (GT) trades at $7.02, up 6.53% today, with a bullish technical signal from moving averages and oscillators. The stock shows deep value metrics with P/E of 4.69 and P/B of 0.66, but faces profitability challenges with negative net income margin of -11.64% and ROE of -52.56%. Recent developments include the company's move to the S&P SmallCap 600 and new NASA lunar tire contract, while Q1 2026 earnings beat estimates despite a net loss.
The outlook remains mixed with analyst consensus at Buy (34.62%) and price target of $8.80 offering 25% upside, but persistent operational headwinds and declining revenue trends pose significant risks. Investment opportunity lies in valuation discount and Goodyear Forward program benefits, though weak tire volumes and negative cash flow projections for 2026 require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
